Verve Therapeutics, Inc. (NASDAQ:VERV) is one of the Stocks With Huge Catalysts on the Horizon. On April 14, Verve ...

If Verve Therapeutics' dramatic stock price activity left your head spinning, you're not alone. Let's take a closer look at what happened so it isn't so easy to get caught off guard in the future.

Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 – VERV© Invezz ...

Shares of Verve Therapeutics (NASDAQ: VERV) were skyrocketing 75.7% higher as of 10:50 a.m. ET on Tuesday. Eli Lilly (NYSE: LLY) and Verve Therapeutics announced a "definitive agreement for Lilly ...

Verve Therapeutics is a biotechnology company focused on developing single-course gene editing medicines for cardiovascular disease (CVD), particularly atherosclerotic cardiovascular disease (ASCVD).

Verve Therapeutics (NASDAQ: VERV) is up 16.5% for the week. The biotech stock, which was as low as $41.52 a share on Monday, climbed as high as $48.39 by Thursday.

Since reporting some early-stage clinical data from one of its gene editing programs on Nov. 12, share prices of Verve Therapeutics (VERV -2.29%) are down 42%.

Verve Therapeutics, a next-generation cardiovascular company, today announced the presentation of new preclinical proof-of-concept data in non-human p ...

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Verve Therapeutics, a biotech company pioneering gene editing medicines to treat cardiovascular disease, today announced the successful completion of a $94 ...

If Verve Therapeutics' dramatic stock price activity left your head spinning, you're not alone. Let's take a closer look at what happened so it isn't so easy to get caught off guard in the future.